Leaderboards/Psychedelics and Drug Studies

Psychedelics and Drug Studies

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Ling-Xiao Shao
Cornell University
2
Manoj K. Doss
Johns Hopkins University
3
Maxemiliano V. Vargas
Multidisciplinary Association for Psychedelic Studies
4
Rafael Moliner
University of Helsinki
5
Richard E. Daws
Wellcome Centre for Human Neuroimaging
6
Natalie Hesselgrave
University of Maryland, Baltimore
7
Balázs Szigeti
Országos Korányi Tbc és Pulmonológiai Intézet
8
Robin von Rotz
Winterthur Museum Garden and Library
9
Dongmei Cao
Center for Excellence in Molecular Cell Science
10
Mario de la Fuente Revenga
Virginia Commonwealth University

Rising Stars Papers

1
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
Psychological Medicine|2024
73 cit.
2
Expectancy Effects in Psychedelic Trials
Biological Psychiatry Cognitive Neuroscience and Neuroimaging|2024
62 cit.
3
Advances in structure-based drug design: The potential for precision therapeutics in psychiatric disorders
Neuron|2024
26 cit.
4
Psilocybin and 2C-B at Encoding Distort Episodic Familiarity
Biological Psychiatry Cognitive Neuroscience and Neuroimaging|2024
7 cit.
5
Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study
Journal of Psychopharmacology|2024
5 cit.
6
Snapshot IP <sub>1</sub> Detection Following 5-HT <sub>2</sub> A Receptor Stimulation in the Mouse Brain
ACS Chemical Neuroscience|2026
1 cit.
7
1. Psilocybin and 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) at Encoding Distort Episodic Familiarity and Positively Bias Emotional Metamemory
Biological Psychiatry|2024
0 cit.
8
Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms: a double-blind, sham-controlled, randomized clinical trial
European Psychiatry|2024
0 cit.
9
Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 2 approved with reservations]
Faculty of 1000 Research Ltd|2024
0 cit.
10
<i>R</i> -MDDMA is a Safer Analogue of MDMA with Therapeutic Potential
ACS Chemical Neuroscience|2026
0 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Margaret A. Klinedinst
Johns Hopkins University
2
Ekaterina Malievskaia
Pathfinder International
3
Allison A. Feduccia
Multidisciplinary Association for Psychedelic Studies
4
Mendel Kaelen
Imperial College London
5
Amy Emerson
Villanova University
6
Maggie A Klinedinst
Johns Hopkins University
7
Frederick S. Barrett
Johns Hopkins University
8
Lee E. Dunlap
Multidisciplinary Association for Psychedelic Studies
9
Joshua Woolley
San Francisco VA Medical Center
10
Leor Roseman
Imperial College London

Emerging Leaders Papers

1
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
New England Journal of Medicine|2022
1.1k cit.
2
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Nature Medicine|2023
387 cit.
3
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Journal of Affective Disorders|2023
165 cit.
4
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Neuropsychopharmacology|2023
164 cit.
5
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Psychopharmacology|2022
158 cit.
6
Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature
Current topics in behavioral neurosciences|2022
88 cit.
7
Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice
Psychedelic Medicine|2023
49 cit.
8
Emerging Challenges for Psychedelic Therapy
JAMA Psychiatry|2023
48 cit.
9
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
Journal of Affective Disorders|2024
35 cit.
10
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Neuropsychopharmacology|2025
21 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Roland R. Griffiths
Johns Hopkins University
2
Robin Carhart‐Harris
University of California, San Francisco
3
Franz X. Vollenweider
University of Zurich
4
Matthias E. Liechti
University Hospital of Basel
5
David Nutt
Imperial College London
6
David Nutt
Imperial College London
7
Rick Doblin
Multidisciplinary Association for Psychedelic Studies
8
David E. Olson
Multidisciplinary Association for Psychedelic Studies
9
Jordi Riba
Universitat Autònoma de Barcelona
10
Johannes G. Ramaekers
Maastricht University

Current Senior Leaders Papers

1
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Journal of Psychopharmacology|2016
2.2k cit.
2
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Psychopharmacology|2006
1.7k cit.
3
Drug harms in the UK: a multicriteria decision analysis
The Lancet|2010
1.7k cit.
4
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
The Lancet Psychiatry|2016
1.5k cit.
5
Trial of Psilocybin versus Escitalopram for Depression
New England Journal of Medicine|2021
1.4k cit.
6
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Frontiers in Human Neuroscience|2014
1.3k cit.
7
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
JAMA Psychiatry|2020
1.3k cit.
8
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Proceedings of the National Academy of Sciences|2012
1.2k cit.
9
Psychedelics Promote Structural and Functional Neural Plasticity
Cell Reports|2018
1.1k cit.
10
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Neuroreport|1998
1k cit.

Reagents for Psychedelics and Drug Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

SimpleChIP® Human gamma-Actin Promoter Primers

#5037$137
View Evidence →
Cell Signaling TechnologyEvidence 65

uPAR (D4Q5S) Rabbit Monoclonal Antibody

#12863$161,351
View Evidence →
Cell Signaling TechnologyEvidence 68

FoxP3 (D6O8R) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

#13282$180,465
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Phospho-MOB1 (Thr12) (D2E3) Rabbit Monoclonal Antibody

#8843$176,415
View Evidence →
Cell Signaling TechnologyEvidence 67

CD68 (E3O7V) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 700 Conjugate)

#37129$458
View Evidence →
Cell Signaling TechnologyEvidence 66

Mouse IL-17A/F Heterodimer Recombinant Protein

#88955$294
View Evidence →